Seladelpar and Reductions in Lipids in Patients With Primary Biliary Cholangitis With and Without Statin Use in the Phase 3 Placebo-Controlled RESPONSE Study

Conference Reports for NATAP

The Liver Meeting
AASLD 2024
Nov 15-19,
San Diego, CA


Seladelpar and Reductions in Lipids in Patients With Primary Biliary Cholangitis With and Without Statin Use in the Phase 3 Placebo-Controlled RESPONSE Study